Publications

Journal Article Epublish 18 citations
Electronic publication date
July 22, 2017

View on Pubmed.gov 27304069 | View on doi.org 10.1371/journal...

Protective Efficacy of Recombinant Turkey Herpes Virus (rHVT-H5) and Inactivated H5N1 Vaccines in Commercial Mulard Ducks against the Highly Pathogenic Avian Influenza (HPAI) H5N1 Clade 2.2.1 Virus.

Search for publications in this journal PLoS One - 11(6):e0156747

Abstract

In Egypt, ducks kept for commercial purposes constitute the second highest poultry population, at 150 million ducks/year. Hence, ducks play an important role in the introduction and transmission of avian influenza (AI) in the Egyptian poultry population. Attempts to control outbreaks include the use of vaccines, which have varying levels of efficacy and failure. To date, the effects of vaccine efficacy has rarely been determined in ducks. In this study, we evaluated the protective efficacy of a live recombinant vector vaccine based on a turkey Herpes Virus (HVT) expressing the H5 gene from a clade 2.2 H5N1 HPAIV strain (A/Swan/Hungary/499/2006) (rHVT-H5) and a bivalent inactivated H5N1 vaccine prepared from clade 2.2.1 and 2.2.1.1 H5N1 seeds in Mulard ducks. A 0.3ml/dose subcutaneous injection of rHVT-H5 vaccine was administered to one-day-old ducklings (D1) and another 0.5ml/dose subcutaneous injection of the inactivated MEFLUVAC was administered at 7 days (D7). Four separate challenge experiments were conducted at Days 21, 28, 35 and 42, in which all the vaccinated ducks were challenged with 106EID50/duck of H5N1 HPAI virus (A/chicken/Egypt/128s/2012(H5N1) (clade 2.2.1) via intranasal inoculation. Maternal-derived antibody regression and post-vaccination antibody immune responses were monitored weekly. Ducks vaccinated at 21, 28, 35 and 42 days with the rHVT-H5 and MEFLUVAC vaccines were protected against mortality (80%, 80%, 90% and 90%) and (50%, 70%, 80% and 90%) respectively, against challenges with the H5N1 HPAI virus. The amount of viral shedding and shedding rates were lower in the rHVT-H5 vaccine groups than in the MEFLUVAC groups only in the first two challenge experiments. However, the non-vaccinated groups shed significantly more of the virus than the vaccinated groups. Both rHVT-H5 and MEFLUVAC provide early protection, and rHVT-H5 vaccine in particular provides protection against HPAI challenge.

References

J Clin Microbiol. 2002 Sep;40(9):3256-60

Emerg Infect Dis. 2006 Feb;12(2):227-34

Emerg Infect Dis. 2006 Dec;12(12):1841-7

Avian Dis. 2008 Jun;52(2):269-77

Cited by 18 citations (total)

Journal Article

Genetic analysis of a novel reassortant H11N9 Isolated from waterfowl in South Korea in 2016.

Electronic publication date January 27, 2018

Search for publications in this journal Virus Genes

Tran Bac Le [...] Sang Heui Seo et al.

Aquatic birds are known to harbor all the known influenza A viruses. In the winter of January 2016, we surveyed...

Journal Article Review

Public health concerns of highly pathogenic avian influenza H5N1 endemicity in Africa.

Electronic publication date December 1, 2017

Search for publications in this journal Vet World

Olubunmi Gabriel Fasanmi [...] Folorunso Oludayo Fasina et al.

Highly pathogenic avian influenza virus (HPAIV) H5N1 was first officially reported in Africa in 2006; thereafter this virus has spread...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances